Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Wesley who wrote (1328)	12/2/1997 10:35:00 PM
From: Miljenko Zuanic	Respond to of 4676

Amateur: Thanks for update on oligonucleotide backbone and sugar modification. After I read several manuscripts on variety of modification induced change on antisense pharmacology, it is obviously that specific modification will be needed for specific target. PK and PD antisense property as well as drug therapeutic index are improved significantly. Interesting, based an current plan for clinical development, that Isis will gradually implement this modification to current antisense in clinical development. I see this as route to chose best modification (each modification needs extensive preclinical study to value its potential) without pressure to rush, and continue development of the first-gen. antisense. mz